Synergistic co-delivery of doxorubicin and melittin using functionalized magnetic nanoparticles for cancer treatment: loading and in vitro release study by LC–MS/MS

References

• Elmore S. Apoptosis: a review of programmed cell death. Toxicol Pathol. 2007;35:495–516.
   PubMed Web of Science ®Google Scholar
• Chabner BA, Roberts TG. Timeline: chemotherapy and the war on cancer. Nat Rev Cancer. 2005;5:65–72.
   PubMed Web of Science ®Google Scholar
• Duan X, Xiao J, Yin Q, et al. Smart pH-sensitive and temporal-controlled polymeric micelles for effective combination therapy of doxorubicin and disulfiram. ACS Nano. 2013;7:5858–5869.
   PubMed Web of Science ®Google Scholar
• Duong HHP, Yung LYL. Synergistic co-delivery of doxorubicin and paclitaxel using multi-functional micelles for cancer treatment. Int J Pharm. 2013;454:486–495.
   PubMed Web of Science ®Google Scholar
• Li N, Zhang P, Huang C, et al. Co-delivery of doxorubicin hydrochloride and verapamil hydrochloride by pH-sensitive polymersomes for the reversal of multidrug resistance. RSC Adv. 2015;5:77986–77995.
   Web of Science ®Google Scholar
• He C, Tang Z, Tian H, et al. Co-delivery of chemotherapeutics and proteins for synergistic therapy. Adv Drug Deliv Rev. 2016;98:64–76.
   PubMed Web of Science ®Google Scholar
• Jhaveri A, Deshpande P, Torchilin V. Stimuli-sensitive nanopreparations for combination cancer therapy. J Control Release. 2014;190:352–370.
   PubMed Web of Science ®Google Scholar
• Omar HEDM. The biological and medical significance of poisonous animals. J Biol Earth Sci. 2013;3:M25–M41.
   Google Scholar
• Vyas VK, Brahmbhatt K, Bhatt H, et al. Therapeutic potential of snake venom in cancer therapy: current perspectives. Asian Pac J Trop Biomed. 2013;3:156–162.
   PubMedGoogle Scholar
• Gajski G, Garaj-Vrhovac V. Melittin: a lytic peptide with anticancer properties. Environ Toxicol Pharmacol. 2013;36:697–705.
   PubMed Web of Science ®Google Scholar
• Moreno M, Giralt E. Three valuable peptides from bee and wasp venoms for therapeutic and biotechnological use: melittin, apamin and mastoparan. Toxins (Basel). 2015;7:1126–1150.
   PubMed Web of Science ®Google Scholar
• Teoh ACL, Ryu KH, Lee EG. One-step purification of melittin derived from Apis mellifera bee venom. J Microbiol Biotechnol. 2017;27:84–91.
   PubMed Web of Science ®Google Scholar
• Moreno M, Zurita E, Giralt E. Delivering wasp venom for cancer therapy. J Control Release. 2014;182:13–21.
   PubMed Web of Science ®Google Scholar
• Oršolić N. Bee venom in cancer therapy. Cancer Metastasis Rev. 2012;31:173–194.
   PubMed Web of Science ®Google Scholar
• Rady I, Siddiqui IA, Rady M, et al. Melittin, a major peptide component of bee venom, and its conjugates in cancer therapy. Cancer Lett. 2017;402:16–31.
   PubMed Web of Science ®Google Scholar
• Soman NR, Lanza GM, Heuser JM, et al. Synthesis and characterization of stable fluorocarbon nanostructures as drug delivery vehicles for cytolytic peptides. Nano Lett. 2008;8:1131–1136.
   PubMed Web of Science ®Google Scholar
• Soman NR, Baldwin SL, Hu G, et al. Molecularly targeted nanocarriers deliver the cytolytic peptide melittin specifically to tumor cells in mice, reducing tumor growth. J Clin Invest. 2009;119:2830–2842.
   PubMed Web of Science ®Google Scholar
• Yamada Y, Shinohara Y, Kakudo T, et al. Mitochondrial delivery of mastoparan with transferrin liposomes equipped with a pH-sensitive fusogenic peptide for selective cancer therapy. Int J Pharm. 2005;303:1–7.
   PubMed Web of Science ®Google Scholar
• Holle L, Song W, Holle E, et al. In vitro- and in vivo-targeted tumor lysis by an MMP2 cleavable melittin-LAP fusion protein. Int J Oncol. 2009;35:829–835.
   PubMed Web of Science ®Google Scholar
• Qian J, Xu M, Suo A, et al. Folate-decorated hydrophilic three-arm star-block terpolymer as a novel nanovehicle for targeted co-delivery of doxorubicin and Bcl-2 siRNA in breast cancer therapy. Acta Biomater. 2015;15:102–116.
   PubMed Web of Science ®Google Scholar
• Abraham SA, Waterhouse DN, Mayer LD, et al. The liposomal formulation of doxorubicin. Meth Enzymol. 2005;391:71–97.
   PubMed Web of Science ®Google Scholar
• Sm A, Sheikh S, Ahmad A, et al. Nanomedicine & nanotechnology bioequivalence study of pegylated doxorubicin hydrochloride liposome (PEGADRIA) and DOXIL® in ovarian cancer patients: physicochemical characterization and pre-clinical studies. J Nanomed Nanotechnol. 2016;7:2157–7439.
   Google Scholar
• Nigam S, Barick KC, Bahadur D. Development of citrate-stabilized Fe3O4 nanoparticles: conjugation and release of doxorubicin for therapeutic applications. J Magn Magn Mater. 2011;323:237–243.
   Web of Science ®Google Scholar
• Munnier E, Cohen-Jonathan S, Linassier C, et al. Novel method of doxorubicin-SPION reversible association for magnetic drug targeting. Int J Pharm. 2008;363:170–176.
   PubMed Web of Science ®Google Scholar
• Semkina A, Abakumov M, Grinenko N, et al. Core–shell–corona doxorubicin-loaded superparamagnetic Fe3O4 nanoparticles for cancer theranostics. Colloids Surf B Biointerfaces. 2015;136:1073–1080.
   PubMed Web of Science ®Google Scholar
• Kaamyabi S, Badrian A, Akbarzadeh A. Synthesis of cross-linked poly(N-isopropylacrylamide) magnetic nanocomposite for application in the controlled release of doxorubicin. PNT. 2017;5:67–75.
   Google Scholar
• Lee GY, Park K, Kim SY, et al. MMPs-specific PEGylated peptide-DOX conjugate micelles that can contain free doxorubicin. Eur J Pharm Biopharm. 2007;67:646–654.
   PubMed Web of Science ®Google Scholar
• Polyak B, Friedman G. Magnetic targeting for site-specific drug delivery: applications and clinical potential. Expert Opin Drug Deliv. 2009;6:53–70.
   PubMed Web of Science ®Google Scholar
• Yang HW, Hua MY, Liu HL, et al. Potential of magnetic nanoparticles for targeted drug delivery. Nanotechnol Sci Appl. 2012;5:73–86.
   PubMedGoogle Scholar
• Alexiou C, Tietze R, Schreiber E, et al. Cancer therapy with drug loaded magnetic nanoparticles magnetic drug targeting. J Magnet Magnet Mater (North-Holland). 2011;323:1404–1407.
   Web of Science ®Google Scholar
• Marcu A, Pop S, Dumitrache F, et al. Magnetic iron oxide nanoparticles as drug delivery system in breast cancer. Appl Surf Sci. 2013;281:60–65.
   Web of Science ®Google Scholar
• Sadighian S, Rostamizadeh K, Hosseini-Monfared H, et al. Doxorubicin-conjugated core–shell magnetite nanoparticles as dual-targeting carriers for anticancer drug delivery. Colloids Surf B Biointerfaces. 2014;117:406–413.
   PubMed Web of Science ®Google Scholar
• Wu W, Wu Z, Yu T, et al. Recent progress on magnetic iron oxide nanoparticles: synthesis, surface functional strategies and biomedical applications. Sci Technol Adv Mater. 2015;16:023501.
   PubMed Web of Science ®Google Scholar
• Akbarzadeh A, Samiei M, Davaran S. Magnetic nanoparticles: preparation, physical properties, and applications in biomedicine. Nanoscale Res Lett. 2012;7:144.
   PubMed Web of Science ®Google Scholar
• Liu J, Sun Z, Deng Y, et al. Highly water-dispersible biocompatible magnetite particles with low cytotoxicity stabilized by citrate groups. Angew Chem Int Ed. 2009;48:5875–5879.
   PubMed Web of Science ®Google Scholar
• Hui C, Shen C, Yang T, et al. Large-scale Fe3O4 nanoparticles soluble in water synthesized by a facile method. J Phys Chem C. 2008;112:11336–11339.
   Web of Science ®Google Scholar
• Hematyar M, Es-Haghi A, Soleimani M, et al. Determination of trace amounts of nystatin in water and vaccine samples using sodium dodecyl sulfate-coated iron oxide magnetic nanoparticles followed by high-performance liquid chromatography–ultraviolet detection. J Iran Chem Soc. 2017;14:2665–2671.
   Web of Science ®Google Scholar
• Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods. 1983;65:55–63.
   PubMed Web of Science ®Google Scholar
• Zhang J, Li J, Shi Z, et al. pH-sensitive polymeric nanoparticles for co-delivery of doxorubicin and curcumin to treat cancer via enhanced pro-apoptotic and anti-angiogenic activities. Acta Biomater. 2017;58:349–364.
   PubMed Web of Science ®Google Scholar
• Chou TC, Talalay P. Quantitative analysis of dose–effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul. 1984;22:27–55.
   PubMedGoogle Scholar
• Dash S, Murthy PN, Nath L, et al. Kinetic modeling on drug release from controlled drug delivery systems. Acta Pol Pharm. 2010;67:217–223.
   PubMed Web of Science ®Google Scholar
• Aji Alex MR, Nehate C, Veeranarayanan S, et al. Self assembled dual responsive micelles stabilized with protein for co-delivery of drug and siRNA in cancer therapy. Biomaterials. 2017;133:94–106.
   PubMed Web of Science ®Google Scholar
• Li Y, Yang L. Driving forces for drug loading in drug carriers. J Microencapsul. 2015;32:255–272.
   PubMed Web of Science ®Google Scholar
• Lübbe AS, Alexiou C, Bergemann C. Clinical applications of magnetic drug targeting. J Surg Res. 2001;95:200–206.
   PubMed Web of Science ®Google Scholar
• Alexiou C, Tietze R, Schreiber E, et al. Cancer therapy with drug loaded magnetic nanoparticles—magnetic drug targeting. J Magn Magn Mater. 2011;323:1404–1407.
   Web of Science ®Google Scholar